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Abstract 
Circulating intercellular adhesion molecule-1 (ICAM-1) and tissue inhibitor of 
metalloproteinases-1 (TIMP-1) have been widely proposed as potential diagnostic 
biomarkers for pancreatic ductal adenocarcinoma (PDAC). We report on serum protein 
levels prior to clinical presentation of pancreatic cancer. Serum ICAM-1 and TIMP-1 were 
measured by ELISA in two case-control sets 1) samples from patients diagnosed with 
pancreatic cancer (n=40), chronic pancreatitis (n=20), benign jaundice due to gall stones 
(n=20) and healthy subjects (n=20); 2) a preclinical set from the UK Collaborative Trial of 
Ovarian Cancer Screening biobank of samples collected from 27 post-menopausal women 
0-12 months prior to diagnosis of pancreatic cancer and controls matched for date of 
donation and centre. Levels of ICAM-1 and TIMP-1 were significantly elevated in set 1 in 
PDAC patients with jaundice compared to PDAC patients without jaundice and both proteins 
were elevated in patients with jaundice due to gall stones. Neither protein was elevated in 
samples taken 0–12 months prior to PDAC diagnosis compared to non-cancer control 
samples. In conclusion, evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 
as biomarkers for earlier diagnosis of pancreatic cancer. Failure to account for obstructive 
jaundice may have contributed to the previous promise of these candidate biomarkers.  
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To the editor 
Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed when the disease is 
advanced. This limits therapeutic options and biomarkers for earlier diagnosis are sought (1). 
Using blood taken at diagnosis of PDAC to identify biomarkers poses intrinsic challenges. 
The levels of blood proteins at diagnosis may accurately represent advanced disease, but 
might not necessarily reflect levels prior to diagnosis. In addition, the sensitivity of some 
markers for the detection of PDAC over healthy controls was recently shown to be 
considerably higher for PDAC patients in the presence of obstructive jaundice compared to 
PDAC patients in the absence of obstructive jaundice (2). Two serum proteins, identified in 
several studies as potential diagnostic biomarkers due to their upregulation in PDAC, are 
ICAM-1 (3-6) and TIMP-1 (3-5, 7-10). In order to determine whether ICAM-1 and TIMP-1 
levels are affected by biliary obstruction we compared samples (Liverpool cohort) taken at 
diagnosis from patients with PDAC (in the presence or absence of jaundice), chronic 
pancreatitis, benign biliary obstruction or from healthy controls. In patients with PDAC, both 
ICAM-1 and TIMP-1 levels were significantly higher than in healthy controls (Figure 1a and 
b), as previously reported (3-10). PDAC patients with biliary obstruction (bilirubin levels >20 
µmol/L) had significantly higher levels of both ICAM-1 (p<0.001) and TIMP-1 (p=0.024) than 
PDAC patients without biliary obstruction (bilirubin levels <20 µmol/L). ICAM-1 and TIMP-1 
levels were also elevated in patients with biliary obstruction due to gall stones (p<0.0001 for 
ICAM-1 and p=0.0001 TIMP-1). Finally these proteins only distinguished PDAC from chronic 
pancreatitis when the PDAC patients had biliary obstruction (p=0.004 for ICAM-1 and 
p=0.014 for TIMP-1, Figure 1a and b). 
Secondly, to determine if these proteins are raised prior to clinical presentation of pancreatic 
cancer, we analysed pre-diagnostic samples collected as part of the UK Collaborative Trial 
of Ovarian Cancer Screening (UKCTOCS)(11), from individuals who went on to develop 
pancreatic cancer during the study, and compared them with their time matched cancer-free 
controls. No significant differences were observed between serum ICAM-1 or TIMP-1 from 
UKCTOCS cases (n=27) and matched controls (n=27) from the time period 0–12 months 
prior to PDAC diagnosis (Figure 1c and d). Of note, although all of the individuals in the 
UKCTOCS cohort were female, the Liverpool cohort contained both males (59/100) and 
females (41/100). Neither ICAM-1 nor TIMP-1 were associated with gender or age in any 
group.  
 
Our study shows that although the levels of both ICAM-1 and TIMP-1 were significantly 
raised at the time of diagnosis in cancer patients compared to healthy controls, the absolute 
increases observed in patients in the absence of biliary obstruction were relatively small 
compared to those seen in the presence of obstruction. Moreover, neither marker was 
effective in distinguishing patients with chronic pancreatitis from PDAC patients in the 
absence of biliary obstruction. We conclude that the initial promise of these two candidates 
as markers of pancreatic cancer was artificially inflated due to failure to account for biliary 
obstruction in cancer patients. Secondly we show that the levels of ICAM-1 and TIMP-1 are 
not significantly elevated in the months leading to a diagnosis of pancreatic cancer, and 
provide little support for the notion that either of these markers will be effective for early 
detection of pancreatic cancer.  
3 
 
 
Acknowledgements 
This work was supported by The National Institute for Health Research Liverpool Pancreas 
Biomedical Research Unit, North West Cancer Research grant CR976 and Cancer 
Research UK grant A12790. UKCTOCS was core-funded by the Medical Research Council, 
Cancer Research UK, and the Department of Health with additional support from the Eve 
Appeal, Special Trustees of Bart’s and the London, and Special Trustees of UCLH. 
UKCTOCS researchers were supported by the National Institute for Health Research 
University College London Hospitals Biomedical Research Centre. 
 
Figure legend 
Figure 1. Analysis of ICAM-1 and TIMP-1 in serum samples. Box and whisker plots for 
serum levels of ICAM-1 (Human sICAM-1/CD54 Quantikine ELISA Kit, R&D Systems, 
Minneapolis, USA) and TIMP-1 (Human TIMP-1 Quantikine ELISA Kit, R&D Systems, 
Minneapolis, USA) measured in the Liverpool cohort samples (a) & (b) and UKCTOCS 
samples (c) & (d). Liverpool cohort details - Gender M/F, Median Age in years (IQR): Healthy 
Controls - 5/15, 38.5 (28.0-37.0); Chronic Pancreatitis – 12/8, 49.5 (44.3-55.0); PDAC non-
obstructed – 10/10, 67.5 (60.0-73.5); PDAC obstructed – 9/11, 68.0 (61.8-72.3); Benign 
Biliary Obstructed – 5/15, 65.5 (56.8-75.3). UKCTOCS cohort details - Gender M/F, Median 
Age in years (IQR): 0-1yr pre-diagnosis cases – (0/27, 68.3 (60.4-70.9); 0-1yr matched 
controls – 0/27, 66.3 (58.5-69.6). Duplicate measurements gave an average CV of 6.4% 
(rho=0.966) for ICAM-1 and 9.9% (rho=0.991) for TIMP-1. Data were log transformed in 
order to remove skewness prior to analysis using JMP software, version 9.0.2. Groups were 
compared using ANOVA and t- tests; p values are shown on graphs for Liverpool cohort (* 
<0.05; ** <0.01; ***<0.001, ****<0.0001). 
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